Menopause & Estrogen Therapies

Ethinylestradiol and Levonorgestrel Tablets IP is a second-generation low-dose Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It synergistically suppresses the mid-cycle LH surge to inhibit ovulation, renders cervical mucus hostile to sperm migration, and alters the endometrium. Second-generation levonorgestrel combinations demonstrate the lowest epidemiological relative risk of venous thromboembolism among combined oral contraceptives. Indicated for prevention of pregnancy, cycle regulation, and treatment of dysmenorrhea.

Ethinylestradiol 0.03 mg and Desogestrel 0.15 mg Tablets is a third-generation low-dose monophasic Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It prevents pregnancy primarily by suppressing pituitary gonadotropin secretion (inhibiting ovulation), thickening cervical mucus to prevent sperm penetration, and altering the endometrium to impair implantation. Desogestrel has high progestogenic potency and low androgenic activity, causing less acne and weight gain than older progestogens.

Ethinylestradiol and Levonorgestrel Tablets IP is a second-generation low-dose Combined Oral Contraceptive (COC) pill on the WHO Model List of Essential Medicines. It synergistically suppresses the mid-cycle LH surge to inhibit ovulation, renders cervical mucus hostile to sperm migration, and alters the endometrium. Second-generation levonorgestrel combinations demonstrate the lowest epidemiological relative risk of venous thromboembolism among combined oral contraceptives. Indicated for prevention of pregnancy, cycle regulation, and treatment of dysmenorrhea.

Ethinylestradiol 0.035 mg and Cyproterone Acetate 2 mg Tablet is a combined hormonal formulation containing an estrogen and a potent anti-androgenic progestogen. Cyproterone competitively blocks androgen receptors and suppresses ovarian androgen synthesis, while Ethinylestradiol increases Sex Hormone-Binding Globulin (SHBG) synthesis, drastically reducing free circulating testosterone. Indicated for the treatment of severe androgen-dependent acne (with or without seborrhea), moderate to severe hirsutism, and polycystic ovary syndrome (PCOS) in women of reproductive age requiring oral contraception.

Estradiol Tablets 2 mg is a bioidentical 17-beta-estradiol formulation identical to endogenous human ovarian estradiol. It restores estrogen receptor activation in the brain, bone, urogenital tract, and cardiovascular system. Indicated for the relief of menopausal symptoms (hot flushes, night sweats, sleep disturbances), management of hypoestrogenism (oophorectomy, primary ovarian insufficiency), endometrial priming in assisted reproduction (frozen embryo transfer / donor egg IVF cycles), and prevention of postmenopausal bone loss.

Conjugated Estrogens 0.625 mg Tablets is a mixture of natural estrogenic substances (principally sodium estrone sulfate and sodium equilin sulfate) on the WHO Model List of Essential Medicines. It binds to nuclear estrogen receptors (ER-alpha and ER-beta), activating gene transcription to replenish declining endogenous estrogen levels in postmenopausal women. Indicated for the management of moderate to severe vasomotor symptoms (hot flashes, night sweats) and vulvovaginal atrophy associated with menopause, and prevention of postmenopausal osteoporosis.

Testosterone Enanthate Injection 250 mg/ml is a long-acting esterified androgen in a sterile sesame/castor oil depot vehicle on the WHO Model List of Essential Medicines. Cleaved slowly by serum esterases, it releases bioidentical testosterone which binds to androgen receptors, restoring normal male physiological testosterone levels, promoting secondary sexual characteristics, nitrogen retention, bone mineralization, erythropoiesis, and libido. Indicated for male hypogonadism (primary testicular failure or hypogonadotropic hypogonadism), delayed puberty in adolescent males, and female-to-male (transmasculine) gender-affirming hormone therapy.